{
  "companies": [
    {
      "id": "blackrock",
      "name": "Blackrock Neurotech",
      "founded": 2008,
      "headquarters": "Salt Lake City, Utah",
      "focus": "Brain-computer interface technology for clinical and research applications",
      "website": "https://blackrockneurotech.com",
      "leadership": {
        "ceo": "Marcus Gerhardt",
        "president": "Florian Solzbacher"
      },
      "products": [
        {
          "name": "NeuroPort Array",
          "type": "Intracortical microelectrode array",
          "electrode_count": 96,
          "fda_status": "510(k) cleared",
          "clearance_number": "K110010",
          "intended_use": "Temporary (<30 day) cortical recording"
        },
        {
          "name": "MoveAgain",
          "type": "Complete BCI system",
          "fda_status": "Breakthrough Device Designation",
          "designation_date": "2021-11-16",
          "intended_use": "Enable paralyzed patients to control devices through thought",
          "target_applications": ["cursor control", "keyboard", "wheelchair", "prosthetics"]
        },
        {
          "name": "Neuralace",
          "type": "Next-generation flexible neural interface",
          "electrode_count": 10000,
          "fda_status": "Research/Development",
          "unveiled": "2022-11",
          "target_applications": ["whole-brain data capture", "vision restoration", "mental health"]
        }
      ],
      "key_metrics": {
        "patient_days": 30000,
        "research_institutions": 500,
        "first_human_implant": 2004
      },
      "regulatory_strategy": {
        "current_pathway": "IDE for MoveAgain pivotal trial",
        "likely_approval_pathway": "PMA",
        "breakthrough_designation": true,
        "tcet_eligible": true
      }
    },
    {
      "id": "neuralink",
      "name": "Neuralink",
      "founded": 2016,
      "headquarters": "Fremont, California",
      "focus": "High-bandwidth, bi-directional brain-computer interfaces",
      "website": "https://neuralink.com",
      "leadership": {
        "founder": "Elon Musk"
      },
      "products": [
        {
          "name": "N1 Implant",
          "type": "Wireless brain implant",
          "electrode_count": 1024,
          "fda_status": "IDE approved",
          "ide_approval_date": "2023-05",
          "clinical_trial": {
            "name": "PRIME Study",
            "nct_number": "NCT06429735",
            "patients_enrolled": 5,
            "first_implant": "2024-01"
          }
        },
        {
          "name": "Blindsight",
          "type": "Visual cortex implant",
          "fda_status": "Breakthrough Device Designation",
          "designation_date": "2024-09",
          "intended_use": "Vision restoration"
        }
      ],
      "regulatory_strategy": {
        "current_pathway": "IDE clinical trial",
        "likely_approval_pathway": "PMA",
        "breakthrough_designation": true
      }
    },
    {
      "id": "synchron",
      "name": "Synchron",
      "founded": 2012,
      "headquarters": "Brooklyn, NY",
      "focus": "Minimally-invasive endovascular BCI",
      "website": "https://synchron.com",
      "leadership": {
        "founder_ceo": "Dr. Tom Oxley"
      },
      "products": [
        {
          "name": "Stentrode",
          "type": "Endovascular brain implant",
          "electrode_count": 16,
          "implantation_method": "Via jugular vein (no open brain surgery)",
          "fda_status": "IDE approved",
          "clinical_trials": [
            {
              "name": "SWITCH Study",
              "location": "Australia",
              "nct_number": "NCT03834857",
              "patients": 7
            },
            {
              "name": "COMMAND Study",
              "location": "United States",
              "nct_number": "NCT05035823",
              "patients": 6,
              "status": "Primary endpoint met (Sept 2024)"
            }
          ]
        }
      ],
      "key_achievements": {
        "first_permanently_implanted_bci_ide": "2021-08",
        "deployment_accuracy": "100%",
        "median_deployment_time_minutes": 20
      },
      "regulatory_strategy": {
        "current_pathway": "Preparing pivotal trial",
        "likely_approval_pathway": "PMA or De Novo",
        "breakthrough_designation": true
      }
    },
    {
      "id": "precision",
      "name": "Precision Neuroscience",
      "founded": 2021,
      "headquarters": "New York, NY",
      "focus": "High-density, minimally-invasive cortical interface",
      "leadership": {
        "founder": "Dr. Benjamin Rapoport"
      },
      "products": [
        {
          "name": "Layer 7-T Cortical Interface",
          "type": "Ultra-thin film electrode array",
          "electrode_count": 1024,
          "fda_status": "510(k) CLEARED",
          "clearance_number": "K242618",
          "clearance_date": "2025-03-30",
          "intended_use": "Temporary (<30 day) cortical recording, monitoring, stimulation"
        }
      ],
      "key_achievement": "First high-channel-count BCI to achieve 510(k) clearance",
      "regulatory_strategy": {
        "strategy": "Hardware-first 510(k), then expand indications",
        "predicates_used": ["K191186 (Ad-Tech)", "K192764 (NeuroOne)"],
        "time_to_clearance_days": 31
      }
    },
    {
      "id": "paradromics",
      "name": "Paradromics",
      "founded": 2015,
      "headquarters": "Austin, Texas",
      "focus": "High-bandwidth, fully implantable BCI for speech restoration",
      "leadership": {
        "founder_ceo": "Matt Angle, PhD"
      },
      "products": [
        {
          "name": "Connexus BCI",
          "type": "High-bandwidth brain implant",
          "electrode_count": 421,
          "fda_status": "IDE approved",
          "ide_approval_date": "2025-11",
          "performance": {
            "bit_rate_bps": 200,
            "latency_ms": 56
          },
          "clinical_trial": {
            "name": "Connect-One Study",
            "target_start": "Q1 2026",
            "indication": "Speech restoration"
          }
        }
      ],
      "key_achievement": "First IDE for speech restoration with fully implantable BCI",
      "regulatory_strategy": {
        "current_pathway": "IDE clinical trial",
        "likely_approval_pathway": "PMA"
      }
    },
    {
      "id": "cognixion",
      "name": "Cognixion",
      "focus": "Non-invasive BCI + AR headset",
      "products": [
        {
          "name": "ONE Headset",
          "type": "EEG-based BCI with AR",
          "fda_status": "Breakthrough Device Designation",
          "designation_date": "2023",
          "intended_use": "Speech-generating device"
        }
      ],
      "key_achievement": "CMS DME supplier accreditation (May 2023)",
      "regulatory_strategy": {
        "pathway": "De Novo likely",
        "reimbursement": "DME pathway"
      }
    },
    {
      "id": "neurolutions",
      "name": "Neurolutions",
      "focus": "Stroke rehabilitation BCI",
      "products": [
        {
          "name": "IpsiHand",
          "type": "Non-invasive BCI for stroke rehab",
          "fda_status": "De Novo CLASSIFIED",
          "clearance_date": "2021",
          "cms_coverage": {
            "decision_date": "2025-01",
            "benefit_category": "Durable Medical Equipment (DME)",
            "cpt_code": "Dedicated code assigned"
          }
        }
      ],
      "key_achievement": "FIRST BCI with dedicated CMS reimbursement"
    }
  ]
}
